PREX2 contributes to radiation resistance by inhibiting radiotherapy-induced tumor immunogenicity via cGAS/STING/IFNs pathway in colorectal cancer

• Published in: BMC medicine 2024-04, Vol.22 (1), p.154-20, Article 154
• Main Authors: Li, Mingzhou, Xiao, Jianbiao, Song, Shasha, Han, Fangyi, Liu, Hongling, Lin, Yang, Ni, Yunfei, Zeng, Sisi, Zou, Xin, Wu, Jieqiong, Wang, Feifei, Xu, Shaowan, Liang, You, Xu, Peishuang, Hong, Huirong, Qiu, Junfeng, Cao, Jianing, Zhu, Qin, Liang, Li
• Format: Article
• Language: English
• Subjects: Analysis; Animal models; Animals; Apoptosis; Assaying; Bioassays; Biomarkers; Cancer; Cancer therapies; Care and treatment; CD8 antigen; CD8-Positive T-Lymphocytes; Cell culture; Cell death; cGAS/STING/IFNs; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Colorectal Neoplasms - radiotherapy; Comet assay; Deoxyribonucleic acid; Diagnosis; Disease Models, Animal; DNA; DNA damage; DNA repair; DNA-dependent protein kinase; Effectiveness; Experiments; Gene Expression; Genes; Guanine Nucleotide Exchange Factors; Health aspects; Humans; Immunogenic cell death; Immunogenicity; Immunohistochemistry; Immunotherapy; Ionizing radiation; Kinases; Lymphocytes; Lymphocytes T; Medical prognosis; Metastases; Mice; Molecular mechanics; Pathology; Patient outcomes; Phosphatidylinositol 3,4,5-triphosphate; PREX2; Proteins; Radiation effects; Radiation therapy; Radiation tolerance; Radioresistance; Radiotherapy; Ribonucleic acid; RNA; Therapeutic targets; Tumorigenesis; Tumors; Western blotting; Xenotransplantation
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/s12916-024-03375-2

Colorectal cancer (CRC) lacks established biomarkers or molecular targets for predicting or enhancing radiation response. Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 2 (PREX2) exhibits intricate implications in tumorigenesis and progression. Nevertheless, the precise role and underlying mechanisms of PREX2 in CRC radioresistance remain unclear. RNA-seq was employed to identify differentially expressed genes between radioresistant CRC cell lines and their parental counterparts. PREX2 expression was scrutinized using Western blotting, real-time PCR, and immunohistochemistry. The radioresistant role of PREX2 was assessed through in vitro colony formation assay, apoptosis assay, comet assay, and in vivo xenograft tumor models. The mechanism of PREX2 was elucidated using RNA-seq and Western blotting. Finally, a PREX2 small-molecule inhibitor, designated PREX-in1, was utilized to enhance the efficacy of ionizing radiation (IR) therapy in CRC mouse models. PREX2 emerged as the most significantly upregulated gene in radioresistant CRC cells. It augmented the radioresistant capacity of CRC cells and demonstrated potential as a marker for predicting radioresistance efficacy. Mechanistically, PREX2 facilitated DNA repair by upregulating DNA-PKcs, suppressing radiation-induced immunogenic cell death, and impeding CD8 T cell infiltration through the cGAS/STING/IFNs pathway. In vivo, the blockade of PREX2 heightened the efficacy of IR therapy. PREX2 assumes a pivotal role in CRC radiation resistance by inhibiting the cGAS/STING/IFNs pathway, presenting itself as a potential radioresistant biomarker and therapeutic target for effectively overcoming radioresistance in CRC.